Impact of the Covid-19 Pandemic on Care of Patients with Diabetes Mellitus at Kitwe Teaching Hospital in 2021

Download Article

DOI: 10.21522/TIJPH.2013.10.04.Art028

Authors : Webster Chewe, James Zulu, Abidan Chansa

Abstract:

Coronavirus disease 2019 (Covid-19) pandemic tested the resilience of the health care system in many countries including Zambia. At the peak, disruption of the global supply chain affected availability of essential commodities needed to manage many health ailments like diabetes mellitus (DM). The study was aimed to understand the challenges faced by DM patients in accessing specialist services at KTH DM specialist clinic during the Covid-19 pandemic in 2021. A cross sectional descriptive study was conducted with a total of 293 participants (109 males and 184 females) recruited using a designed structured questionnaire and results analyzed using Microsoft Office Excel 2016 and the Statistical Package for Social Sciences (SPSS) version 16.0 software. The mean age was 54.0 ± 13.0 years old with 78(26.6%) being below the age of 45 years. 197(67.2%) were married and 157(53.6%) had primary education or less. 216(73.7%) and 222(75.8%) were earning <US$5.00 per day before and during Covid-19 pandemic respectively while the majority were spending one fifth of their earned income on medication from private pharmacies alone. 231(78.8%) had T2DM while 149(50.8%) had high plasma glucose levels; high BMI, high waist circumference and hypertension 184(62.8%). The study suggested that disruption of outpatient services led to patients presenting with high plasma glucose levels, poorly controlled weight (high BMI and high waist circumference). Commonest complications included hypertension and peripheral neuropathy. There is a need to devise a more pragmatic and resilient healthcare system in future to minimize the effects of any pandemic should they arise.

Keywords: Covid-19, Diabetes medication, Diabetes mellitus, Essential healthcare services, Hypertension, Lifestyle modification.

References:

[1] R. (chair) et al. Williams, IDF Diabetes Atlas 9th. 2019.

[2] American Diabetes Association, “Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers,” Clin. Diabetes, vol. 40, no. 1, pp. 10–38, Jan. 2022, doi: 10.2337/cd22-as01.

[3] A. Ramachandran, C. Snehalatha, E. Latha, M. Manoharan, and V. Vijay, “Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population,” Diabetes Res. Clin. Pract., vol. 44, no. 3, pp. 207–213, Jun. 1999, doi: 10.1016/S0168-8227(99)00024-8.

[4] T. I. A. SØrensen, “The changing lifestyle in the world: Body weight and what else?” in Diabetes Care, 2000, vol. 23, no. SUPPL. 2.

[5] N. G. Forouhi and N. J. Wareham, “Epidemiology of diabetes,” Medicine (Baltimore)., vol. 38, no. 11, pp. 602–606, Nov. 2010, doi: 10.1016/j.mpmed.2010.08.007.

[6] S. Mallapaty, “Evidence suggests the coronavirus might trigger diabetes,” Nature, pp. 16–17, 2020.

[7] S. Peric and T. M. Stulnig, “Diabetes and Covid-19,” Wien. Klin. Wochenschr., vol. 132, no. 13–14, pp. 356–361, Jul. 2020, doi: 10.1007/s00508-020-01672-3.

[8] L. Marchand, M. Pecquet, and C. Luyton, “Type 1 diabetes onset triggered by Covid-19,” Acta Diabetol., vol. 57, no. 10, pp. 1265–1266, Oct. 2020, doi: 10.1007/s00592-020-01570-0.

[9] S. Lou Bailey et al., “Diabetes mellitus in Zambia and the Western Cape province of South Africa: Prevalence, risk factors, diagnosis and management,” Diabetes Res. Clin. Pract., vol. 118, pp. 1–11, 2016, doi: 10.1016/j.diabres.2016.05.001.

[10] Zambia Statistical Agency, “The Zambia Statistical Agency (ZamStats).” https://www.zamstats.gov.zm (accessed May 20, 2021).

[11] IMF, World Economic Outlook: Recovery During a Pandemic, no. May. 2021.

[12] African Development Bank (AfDB) Group, “Zambia Economic Outlook,” 2021. https://www.afdb.org/en/countries-southern-africa-zambia/zambia-economic-outlook (accessed May 20, 2021).

[13] Zambia Ministry of Finance, “Annual Economic Report - 2019,” Lusaka, 2020. [Online]. Available: https://www.mof.gov.zm/?wpfb_dl=264.

A.      Sharma, P. Gupta, and R. Jha, “Covid-19: Impact on Health Supply Chain and Lessons to Be Learnt,” J. Health Manag., vol. 22, no. 2, pp. 248–261, Jun. 2020, doi: 10.1177/0972063420935653.

[14] V. Haldane et al., “Health systems resilience in managing the Covid-19 pandemic: lessons from 28 countries,” Nat. Med., vol. 27, no. 6, pp. 964–980, Jun. 2021, doi: 10.1038/s41591-021-01381-y.

[15] A. Sagan et al., “Covid-19 and Health Systems Resilience: Lessons Going Forward,” Eurohealth (Lond)., vol. 26, no. 2, pp. 20–24, 2020, [Online]. Available: https://apps.who.int/iris/bitstream/handle/10665/336290/Eurohealth.

[16] A. Desta et al., “Impacts of Covid-19 on essential health services in Tigray, Northern Ethiopia: A pre-post study,” PLoS One, vol. 16, no. 8, p. e0256330, Aug. 2021, doi: 10.1371/journal.pone.0256330.

[17] M. Zakoji and T. Sundararaman, “Emerging good practices and lessons learnt to maintain essential health services during the Covid-19 pandemic,” WHO South-East Asia J. Public Heal., vol. 10, no. 3, p. 26, 2021, doi: 10.4103/2224-3151.309868.

[18] Z. Aranda et al., “Disruptions in maternal health service use during the Covid-19 pandemic in 2020: Experiences from 37 health facilities in low-income and middle-income countries,” BMJ Glob. Heal., vol. 7, no. 1, pp. 1–10, 2022, doi: 10.1136/bmjgh-2021-007247.

[19] K. Blanchet et al., “Protecting essential health services in low-income and middle-income countries and humanitarian settings while responding to the Covid-19 pandemic,” BMJ Glob. Heal., vol. 5, no. 10, pp. 1–9, 2020, doi: 10.1136/bmjgh-2020-003675.

[20] World Health Organization, “Covid-19 continues to disrupt essential health services in 90% of countries,” 2021. https://www.who.int/news/item/23-04-2021-covid-19-continues-to-disrupt-essential-health-services-in-90-of-countries (accessed May 20, 2021).

[21] World Health Organization, “Nearly 1 in 5 Covid-19 deaths in the African region linked to diabetes,” 2020. https://www.afro.who.int/news/nearly-1-5-covid-19-deaths-african-region-linked-diabetes (accessed May 20, 2021).

[22] A. Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” Lancet, vol. 395, no. 10223, pp. 497–506, Feb. 2020, doi: 10.1016/S0140-6736(20)30183-5.

[23] A. Flyvbjerg, “Pathogenesis of Microvascular Complications,” in Textbook of Diabetes, Chichester, UK: John Wiley & Sons, Ltd, 2016, pp. 541–553.

[24] M. Khamaisi, G. L. King, K. Park, and Q. Li, “Pathogenesis of Microvascular Complications,” in Diabetes Complications, Comorbidities and Related Disorders, 2nd ed., Springer, Cham, 2020, pp. 161–201.

[25] M. J. Fowler, “Microvascular and Macrovascular Complications of Diabetes,” Clin. Diabetes, vol. 26, no. 2, pp. 77–82, Apr. 2008, doi: 10.2337/diaclin.26.2.77.

[26] Diabetes Control and Complications Trial Research Group, “Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial,” J. Pediatr., vol. 125, no. 2, pp. 177–188, Aug. 1994, doi: 10.1016/S0022-3476(94)70190-3.

[27] UK Prospective Diabetes Study (UKPDS) Group, “Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34),” Lancet, vol. 352, no. 9131, pp. 854–865, Sep. 1998, doi: 10.1016/S0140-6736(98)07037-8.

[28] Z. He and G. L. King, “Microvascular complications of diabetes,” Endocrinol. Metab. Clin. North Am., vol. 33, no. 1, pp. 215–238, Mar. 2004, doi: 10.1016/j.ecl.2003.12.003.

[29] G. Rayman et al., “Guidelines for the management of diabetes services and patients during the COVID‐19 pandemic,” Diabet. Med., vol. 37, no. 7, pp. 1087–1089, Jul. 2020, doi: 10.1111/dme.14316.

[30] A. Kazi and L. Blonde, Classification of diabetes mellitus, vol. 21, no. 1. 2001.

[31] M. A. B. Khan, M. J. Hashim, J. K. King, R. D. Govender, H. Mustafa, and J. Al Kaabi, “Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends,” J. Epidemiol. Glob. Health, vol. 10, no. 1, p. 107, 2019, doi: 10.2991/jegh.k.191028.001.

[32] H. A. van Dam, F. G. van der Horst, L. Knoops, R. M. Ryckman, H. F. J. M. Crebolder, and B. H. W. van den Borne, “Social support in diabetes: a systematic review of controlled intervention studies,” Patient Educ. Couns., vol. 59, no. 1, pp. 1–12, Oct. 2005, doi: 10.1016/j.pec.2004.11.001.

[33] J. L. Strom and L. E. Egede, “The Impact of Social Support on Outcomes in Adult Patients with Type 2 Diabetes: A Systematic Review,” Curr. Diab. Rep., vol. 12, no. 6, pp. 769–781, Dec. 2012, doi: 10.1007/s11892-012-0317-0.

[34] K. Y. Chan, W. Cockshaw, K. Smith, E. Holmes-Truscott, F. Pouwer, and J. Speight, “Social support and self-care outcomes in adults with diabetes: The mediating effects of self-efficacy and diabetes distress. Results of the second diabetes MILES – Australia (MILES-2) study,” Diabetes Res. Clin. Pract., vol. 166, p. 108314, Aug. 2020, doi: 10.1016/j.diabres.2020.108314.

[35] K. D. Adam et al., “Factors affecting diabetes knowledge in Type 2 diabetic veterans,” Diabetologia, vol. 46, no. 8, pp. 1170–1178, Aug. 2003, doi: 10.1007/s00125-003-1161-1.

[36] F. Fernanda et al., “Relationship between knowledge, attitude , education and duration of disease in individuals with diabetes mellitus,” Acta Paul Enferm, vol. 25, no. 2, pp. 284–290, 2012.

[37] M. Delamater, “Improving Patient Adherence,” Clin. Diabetes, vol. 24, no. 2, pp. 71–77, Apr. 2006, doi: 10.2337/diaclin.24.2.71.

[38] A. Kalungia, M. Mwale, I. S. Sondashi, B. Mweetwa, P. Yassa, and G. Kadimba, “Availability of Essential Antihypertensive and Antidiabetic Medicines in Public Health Facilities in Lusaka District, Zambia,” Med. J. Zambia, vol. 44, no. 3, pp. 140–148, 2017.

[39] H. Kaiser, L. Hehman, B. C. Forsberg, W. M. Simangolwa, and J. Sundewall, “Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia,” PLoS One, vol. 14, no. 12, p. e0226169, Dec. 2019, doi: 10.1371/journal.pone.0226169.

[40] amnath S. Ramanathan, “Correlation of duration, hypertension and glycemic control with microvascular complications of diabetes mellitus at a tertiary care hospital,” Integr. Mol. Med., vol. 4, no. 1, 2017, doi: 10.15761/IMM.1000272.

[41] S. Zoungas et al., “Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds,” Diabetologia, vol. 55, no. 3, pp. 636–643, Mar. 2012, doi: 10.1007/s00125-011-2404-1.

[42] T.-C. Li et al., “Glycemic control paradox: Poor glycemic control associated with higher one-year and eight-year risks of all-cause hospitalization but lower one-year risk of hypoglycemia in patients with type 2 diabetes,” Metabolism, vol. 64, no. 9, pp. 1013–1021, Sep. 2015, doi: 10.1016/j.metabol.2015.05.004.

[43] L. Perreault et al., “Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program,” Diabetes Care, vol. 31, no. 7, pp. 1416–1421, Jul. 2008, doi: 10.2337/dc07-2390.

[44] M. A. M. Jacobs-van der Bruggen et al., “Cost-Effectiveness of Lifestyle Modification in Diabetic Patients,” Diabetes Care, vol. 32, no. 8, pp. 1453–1458, Aug. 2009, doi: 10.2337/dc09-0363.

[45] S. Carlsson, N. Hammar, and V. Grill, “Alcohol consumption and type 2 diabetes,” Diabetologia, vol. 48, no. 6, pp. 1051–1054, Jun. 2005, doi: 10.1007/s00125-005-1768-5.